Product news

Share this article:
Mylan received FDA approval for generic versions of AstraZeneca's hypertension treament, Plendil extended-release tablets. Mylan said it received approval for 2.5 mg, 5 mg, and 10 mg doses and already started shipping the product.

Pfizer received approval to market its anti-tumor drug/kinase inhibitor Sutent capsule 12.5 mg (sunitinib malate) in Japan. Sutent is indicated for gastrointestinal stromal tumor after failure of imatinib treatment due to resistance and for renal cell carcinoma not indicated for curative resection and metastatic renal cell carcinoma. Sutent was approved in the US in January 2006.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.

Painkiller maker Acura gets NIH grant

The $300,000 grant will go towards an abuse-deterrent technology.

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.